Action XOMA Royalty - XOMAO

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Dernier

25,42

Prix Achat

25,03

Prix Vente

26,05

Volume échangé

0,00 Fourchette du Jour 0,00

0,00 Plage de 52 semaines 0,00

Cap du marché

299,558M

Clôture Veille

25,42

Ouverture

Dernière Transaction

Dernière heure de transaction

Volume financier

VWAP

Volume moyen (3 m)

Actions en circulation

11 782 723

Rendement du Dividende

8.24%

Ratio Cours sur Bénéfices

-5,92

Bénéfice par action (BPA)

-3,47

Chiffre d'affairess

4,76M

Bénéfice net

-40,83M

XOMA Corp is a biotechnology royalty aggregator playing a unique role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnolo... XOMA Corp is a biotechnology royalty aggregator playing a unique role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Show more

Secteur

Pharmaceutical Preparations

Industrie

Pharmaceutical Preparations

Site Web

www.xoma.com

Siège social

Wilmington, Delaware, USA

Fondé

XOMA Royalty Corporation est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker XOMAO. Le dernier cours de clôture d'XOMA Royalty était de US$25,42. Au cours de la dernière année, les actions de XOMA Royalty ont été négociées dans une fourchette de prix de US$ 0,00 à US$ 0,00.

XOMA Royalty compte actuellement 11 782 723 actions en circulation. La capitalisation boursière d'XOMA Royalty est de US$299,56 million. XOMA Royalty a un ratio cours/bénéfice (ratio PE) de -5.92.

XOMA Royalty to Present at Investor Conferences in March

EMERYVILLE, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech...

XOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

EMERYVILLE, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech...

XOMA Royalty Declares Quarterly Preferred Stock Dividends

EMERYVILLE, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today...

XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio

Seralutinib becomes XOMA Royalty’s seventh Phase 3 royalty asset, further building the late-stage pipeline...

XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities

Zevra’s MIPLYFFA™ (arimoclomol) received FDA approval and became the sixth commercial asset in XOMA Royalty’s...

XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience

XOMA Royalty has acquired 50 percent of Twist’s existing royalty and milestone economics for $15 million XOMA...

Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)

MIPLYFFA™ is the first therapy approved for use in patients with NPC, a rare genetic disorder XOMA Royalty is...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	PR
4	0	0	0	0	0	0	0	PR
12	0	0	0	0	0	0	0	PR
26	0	0	0	0	0	0	0	PR
52	0	0	0	0	0	0	0	PR
156	0	0	0	0	0	0	0	PR
260	0	0	0	0	0	0	0	PR

XOMAO - Frequently Asked Questions (FAQ)

What is the current XOMA Royalty share price?

The current share price of XOMA Royalty is US$ 25,42

How many XOMA Royalty shares are in issue?

XOMA Royalty has 11 782 723 shares in issue

What is the market cap of XOMA Royalty?

The market capitalisation of XOMA Royalty is USD 299,56M

What is the 1 year trading range for XOMA Royalty share price?

XOMA Royalty has traded in the range of US$ 0,00 to US$ 0,00 during the past year

What is the PE ratio of XOMA Royalty?

The price to earnings ratio of XOMA Royalty is -5,92

What is the cash to sales ratio of XOMA Royalty?

The cash to sales ratio of XOMA Royalty is 50,77

What is the reporting currency for XOMA Royalty?

XOMA Royalty reports financial results in USD

What is the latest annual turnover for XOMA Royalty?

The latest annual turnover of XOMA Royalty is USD 4,76M

What is the latest annual profit for XOMA Royalty?

The latest annual profit of XOMA Royalty is USD -40,83M

What is the registered address of XOMA Royalty?

The registered address for XOMA Royalty is CORPORATION TRUST CENTER, 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801

What is the XOMA Royalty website address?

The website address for XOMA Royalty is www.xoma.com

Which industry sector does XOMA Royalty operate in?

XOMA Royalty operates in the PHARMACEUTICAL PREPARATIONS sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
AREBAmerican Rebel Holdings Inc	US$ 0,527 (73,41%)	7,32M
HCTIHealthcare Triangle Inc	US$ 0,4636 (42,65%)	8,28M
HFBLHome Federal Bancorp Inc of Louisiana	US$ 17,99 (42,38%)	1
CSPICSP Inc	US$ 22,00 (41,94%)	16
SSPEW Scripps Company	US$ 1,945 (36,01%)	831,35k
HEPAHepion Pharmaceuticals Inc	US$ 0,0497 (-40,83%)	5,54M
SYRSSyros Pharmaceuticals Inc	US$ 0,0969 (-28,75%)	1,17M
SERASera Prognostics Inc	US$ 3,01 (-28,67%)	4
ZYXIZynex Inc	US$ 5,08 (-27,43%)	2,82k
TNONTenon Medical Inc	US$ 1,14 (-24,50%)	258,65k
STISolidion Technology Inc	US$ 0,1406 (11,50%)	48,58M
HCTIHealthcare Triangle Inc	US$ 0,4636 (42,65%)	8,28M
AREBAmerican Rebel Holdings Inc	US$ 0,527 (73,41%)	7,32M
HEPAHepion Pharmaceuticals Inc	US$ 0,0497 (-40,83%)	5,54M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	US$ 8,45 (6,83%)	5,25M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

XOMA Royalty Corporation (XOMAO)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

À propos de XOMA Royalty Corporation

XOMAO Dernières nouvelles

XOMA Royalty to Present at Investor Conferences in March

XOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

XOMA Royalty Declares Quarterly Preferred Stock Dividends

XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio

XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities

XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience

Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)

XOMA Royalty Declares Quarterly Preferred Stock Dividends

XOMA Royalty to Present at Upcoming Investor Conferences in September

XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities

XOMA Royalty to Present at Investor Conferences in March

XOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

XOMA Royalty Declares Quarterly Preferred Stock Dividends

XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio

XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities

XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience

Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)

XOMA Royalty Declares Quarterly Preferred Stock Dividends

XOMAO - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	PR
4	0	0	0	0	0	0	0	PR
12	0	0	0	0	0	0	0	PR
26	0	0	0	0	0	0	0	PR
52	0	0	0	0	0	0	0	PR
156	0	0	0	0	0	0	0	PR
260	0	0	0	0	0	0	0	PR

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	PR
4	0	0	0	0	0	0	0	PR
12	0	0	0	0	0	0	0	PR
26	0	0	0	0	0	0	0	PR
52	0	0	0	0	0	0	0	PR
156	0	0	0	0	0	0	0	PR
260	0	0	0	0	0	0	0	PR

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

XOMA Royalty Corporation (XOMAO) Cours

XOMA Royalty Corporation (XOMAO)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

À propos de XOMA Royalty Corporation

XOMAO Dernières nouvelles

XOMA Royalty to Present at Investor Conferences in March

XOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

XOMA Royalty Declares Quarterly Preferred Stock Dividends

XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio

XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities

XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience

Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)

XOMA Royalty Declares Quarterly Preferred Stock Dividends

XOMA Royalty to Present at Upcoming Investor Conferences in September

XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities

XOMA Royalty to Present at Investor Conferences in March

XOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

XOMA Royalty Declares Quarterly Preferred Stock Dividends

XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio

XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities

XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience

Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)

XOMA Royalty Declares Quarterly Preferred Stock Dividends

XOMAO - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	PR
4	0	0	0	0	0	0	0	PR
12	0	0	0	0	0	0	0	PR
26	0	0	0	0	0	0	0	PR
52	0	0	0	0	0	0	0	PR
156	0	0	0	0	0	0	0	PR
260	0	0	0	0	0	0	0	PR